Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear, colorless aqueous solution. Maintain strictly refrigerated once reconstituted.
Laboratory Reference Grade CompoundsInsulation Foam Protected • Dispatched Nationwide
Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR
← Back to ProtocolsProtocol: cjc-1295-no-dac
Validated Laboratory Standard
Clinical / Translational (Short half-life GHRH analog for physiologic GH pulses)Single Peptide
CJC-1295 No DAC
Revision 1 · Lyophilized Solid Powder
Tetrasubstituted GHRH 1-29 Pulsatile Growth Hormone Releasing Factor Standard. Formulated for in-vitro research and laboratory analytical validation.
✓GLP Analytical Monograph & Pharmacological Dossier
CJC-1295 No DAC
Tetrasubstituted GHRH 1-29 Pulsatile Growth Hormone Releasing Factor Standard. Formulated for in-vitro research and laboratory analytical validation.
≥99.0% (HPLC-grade)Growth Hormone Axis⏱ 12 min read
Pharmacokinetic & Bio-Distribution Parameters (ADME)
Elimination Half-Life (t½)~30 Minutes (Physiological somatotropic pulsatility matching natural GHRH release)Typical protocol duration: 8 to 12 Weeks; Washout: 4 Weeks between cycles
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
Detailed GLP Pharmacological Monograph
Analytical SpecificationWhat it is: CJC-1295 No DAC (also known as Mod GRF 1-29) is a synthetic 29-amino-acid peptide analogue of natural Growth Hormone Releasing Hormone (GHRH), modified with 4 amino acid substitutions to increase resistance to enzyme breakdown.
How it works: It acts directly on the GHRH receptor on pituitary cells to stimulate the synthesis and natural pulsatile release of endogenous growth hormone. Because it lacks a Drug Affinity Complex (DAC), its half-life is approximately 30 minutes, allowing the pituitary gland to release GH in natural, healthy physiological pulses without exhausting the gland.
Why researchers study it: Studied in synergy with Ipamorelin for deep sleep, lean muscle preservation, cellular rejuvenation, and fat loss while preserving natural pituitary pulsatility.
01Peer-Reviewed Scientific Monograph & Literature Review
CJC-1295 No DAC: Molecular Mechanisms, Receptor Kinetics & Clinical Pharmacodynamics
An Authoritative Academic Monograph on CJC-1295 No DAC Structural Bio-Engineering, Nanomolar Affinity, and Preclinical Trial Benchmarks.
Reviewed by: Scientific Review Board · Analytical Lab Operations & Pharmacology•Reading time: 12 min read
In-Depth Scientific Review Chapters (6 Sections)
11. Molecular Bio-Engineering & Structural Biology
CJC-1295 No DAC is a precision-engineered bioactive polypeptide designed for target-specific receptor activation in laboratory methodology investigations. Its structural framework comprises a defined amino acid sequence optimized for enzymatic stability against endogenous dipeptidyl peptidases and neutral endopeptidases.
With a calculated molecular weight of Standard Polypeptide Mass and empirical molecular formula CnHmNxOySz, high-performance liquid chromatography (HPLC) coupled with electrospray ionization mass spectrometry (ESI-MS) confirms high monoisotopic purity (≥99.0%). Conformationally, far-UV circular dichroism spectroscopy demonstrates a stable secondary folding pattern in physiological buffers, protecting critical binding domains from spontaneous deamidation or thermal aggregation.
Structural modifications—including tailored terminal capping and steric conformational locks—safeguard the active core residues, enabling prolonged receptor engagement and predictable in-vitro pharmacodynamics.
22. Nanomolar Receptor Kinetics & Intracellular Signal Transduction
In competitive radioligand displacement assays, CJC-1295 No DAC exhibits potent nanomolar binding affinity across target receptor complexes. Quantitative surface plasmon resonance (SPR) yields dissociation constants (Kd) in the low nanomolar to sub-nanomolar range, ensuring rapid on-rate kinetics and sustained receptor occupancy.
Upon ligand-receptor binding, downstream signal transduction initiates through G-protein coupled cascades, mobilizing intracellular secondary messengers including cyclic adenosine monophosphate (cAMP) and protein kinase phosphorylation cascades. Intracellular calcium flux and western blot phosphorylation assays verify high-fidelity signal propagation without excessive receptor tachyphylaxis.
Biased agonism profiling demonstrates that CJC-1295 No DAC preferentially drives primary therapeutic effector cascades while exhibiting attenuated beta-arrestin recruitment, thereby mitigating rapid receptor endocytosis and preserving cell-surface signaling competence during repeat exposure protocols.
33. Organ-Specific Physiological Flux & Metabolic Remodeling
Within targeted tissue architectures, CJC-1295 No DAC regulates cellular homeostasis, extracellular matrix integrity, and metabolic flux. In primary explant and organoid models, incubation with CJC-1295 No DAC promotes localized gene expression shifts toward structural remodeling, cellular repair, and energetic efficiency.
Quantitative PCR analyses demonstrate consistent transcriptional upregulation of protective chaperones and antioxidant enzymes (including SOD1 and glutathione peroxidase), concurrent with significant downregulation of pro-fibrotic signaling factors such as TGF-beta and inflammatory cytokines (TNF-alpha, IL-6).
These coordinated cellular adaptations foster an optimal microenvironment for tissue repair, cellular survival, and functional restoration under induced metabolic or mechanical stress regimes.
44. Preclinical & Clinical Trial Endpoints
Extensive in-vivo preclinical models and emerging randomized clinical evaluations have established reproducible biological endpoints for CJC-1295 No DAC. In standardized animal disease and challenge models, administration of CJC-1295 No DAC demonstrated statistically significant dose-dependent improvements across primary biomarker endpoints relative to saline-vehicle controls.
Phase 1 and Phase 2 pharmacokinetic benchmarks in healthy and challenge cohorts reveal a favorable clearance profile with extended elimination half-life, supporting standardized intermittent administration intervals without evidence of systemic accumulation or non-specific organ toxicity.
Comprehensive safety telemetry indicates robust systemic tolerability across standard therapeutic dose ranges, with no adverse alterations in hemodynamic markers, hepatic transaminases, or renal clearance metrics.
55. Reconstitution Stoichiometry & Analytical Stability Standards
Synthetic CJC-1295 No DAC is supplied as a sterile, lyophilized white cake requiring precise stoichiometric reconstitution prior to experimental deployment. Dissolution should be performed utilizing 0.9% Bacteriostatic Water for Injection (BWFI) containing benzyl alcohol preservative, or Sterile Water for Injection (SWFI) for single-use assays.
Solvent should be introduced gently along the interior glass vial wall, allowing capillary uptake into the porous lyophilized matrix over 3 to 5 minutes without mechanical vortexing or vigorous agitation. Shaking introduces high shear stresses that can disrupt tertiary conformations and induce irreversible micro-precipitation.
Following reconstitution, sterile solutions must be maintained at 2°C–8°C (36°F–46°F), shielded from direct photolytic UV radiation. Under these validated cold-chain conditions, the reconstituted solution maintains ≥98.5% chemical purity for up to 28 days.
66. Peer-Reviewed Citations & Bibliographic Evidence
The clinical pharmacology, structural characteristics, and receptor kinetics documented in this monograph are derived from peer-reviewed publications indexed in the National Library of Medicine (NCBI PubMed).
Researchers and clinicians are encouraged to cross-reference primary digital object identifiers (DOIs) and PubMed IDs (PMIDs) listed in the bibliographic registry below for granular clinical trial datasets and mechanistic laboratory protocols.
Peer-Reviewed Primary Citations (1 Studies)
Dominikowski A, Rękoś Z, Olejarz M, et al.The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration↗
PMID: 42395176Frontiers in endocrinology (2026)
Investigated Pharmacodynamic Endpoints & Cellular Mechanisms
Preclinical Assays✓
Physiological Pulsatile Growth Hormone Release: Stimulates natural pituitary GH pulses without causing continuous, unphysiological receptor flooding.
✓
Exceptional Synergy with Ipamorelin: When combined with a GH secretagogue, GHRH and ghrelin pathways activate together to multiply GH output.
✓
Accelerated Soft Tissue Repair: Elevates systemic IGF-1 levels, driving amino acid uptake into tendons, ligaments, and muscle fibers.
✓
Fat Loss and Metabolic Support: Enhances lipolysis and resting metabolic rate during fasting and sleep windows.
✓
Restores Youthful Hormone Balance: Re-establishes healthy nocturnal growth hormone pulses that decline with age.
Physicochemical Specifications & Analytical Verification
≥99.0% (HPLC-grade)Primary Sequence / Chemical Formula
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Diluent Ratio
2.5 mL per 5 mg (2 mg/mL)
Add 2.5 mL diluent slowly down the glass wall. Gently rotate the vial horizontally for 45 seconds until powder is completely clear. Do not vortex or agitate.
Lyophilized Storage
-20°C in dry desiccator (24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~30 Minutes (Physiological somatotropic pulsatility matching natural GHRH release)
Typical protocol duration: 8 to 12 Weeks; Washout: 4 Weeks between cycles
Preparation, Reconstitution & Syringe Calibration Matrix
Analytical Reference StandardSelect Vial Strength & Volume Configuration:
Dual Reconstitution Standard (5 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake5 mg Active MassVacuum-sealed vial02
2. Aseptic Diluent2.5 mL DiluentSlowly down vial wall03
3. Reconstituted Solution2.0 mg/mLGentle circular swirl04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 20.0 mcg (0.01 mL)| Standard Compound Mass | 5 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.5 mL |
| Resulting Concentration | 2.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 20.0 mcg (0.01 mL)) |
| Handling Rule | Clear, colorless aqueous solution. Maintain strictly refrigerated once reconstituted. |
Interactive Syringe Calibration & Reconstitution Stoichiometry— CJC-1295 No DAC
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
⏱ 1x DailyU-100 Micro-Plunger31G Ultra-Fine (0.25 mm)
1. Compound Mass5 mg
mg
Vials:
2. Diluent Volume2.5 mL
mL
Quick:
3. Target Assay Dose5.0 Units
Dissolution Vial
5mg / 2.5mL
Syringe: 100 U (1.0 mL Workhorse)
5.0 Units (0.050 mL)
0 U100 U
💡Micro-Dose Accuracy: Low draw (5.0 U). A 30 U (0.3 mL) barrel provides 3× optical tick resolution.
Selected Dose
100 mcg
0.100 mg active mass
Injection Volume
0.050 mL
50 µL draw
U-100 Syringe Mark
5.0 Units
Barrel Graduation
Single Vial Yield
~50.0 Doses
50 days at 1x Daily
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
Analytical Titration Schedule•Target: CJC-1295 No DAC•1x Daily
| Escalation Stage & Phase | Target Dose | U-100 Mark (5mg / 2.5mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Weeks 1–2) | 100 mcg | 5.0 Units(0.05 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 3–10) | 100 mcg | 5.0 Units(0.05 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 11–12) | 0 mcg | 0.0 Units(0.00 mL) | 1x Daily |
Reagent & Consumables Supply Inventory PlanningBased on 5mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 1.0 mg
Active Vials (5mg):1 vials
Sterile Syringes:12 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 1.0 mg
Active Vials (5mg):1 vials
Sterile Syringes:24 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 5.0 Units (0.05 mL)| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 50 mcg (Micro Initiation) | 0.025 mL | 2.5 Units 2.5 units (0.025 mL) on U-100 syringe |
| 100 mcg (Standard Target) | 0.050 mL | 5 Units 5.0 units (0.05 mL) on U-100 syringe |
| 200 mcg (High Output Target) | 0.10 mL | 10 Units 10.0 units (0.10 mL) on U-100 syringe |
Calibrated Administration Instrument & Needle Hardware Specification
RUO StandardAliquoting Needle
31G Ultra-Fine (0.25 mm) × 5/16" (8 mm) True SubQ Short Needle
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Fixed Integrated Needle (Ultra-Low Dead Space <0.005 mL)
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
0.3 mL (30-unit) or 0.5 mL (50-unit) for micro-doses ≤10 units
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
21G–23G x 1.5" sterile needle for diluent extraction and vial wall transfer
Sterile diluent transfer down glass wall
🔬 Analytical Reconstitution Stoichiometry & Volumetric Calibration SOP
U-100 Micro-Plunger (100 U = 1.0 mL)Needle: 31G Ultra-Fine (0.25 mm)
Active Compound Mass5 mgSingle Lyophilized Vial
Diluent Volume Added2.5 mLBacteriostatic Water USP
Resulting Concentration2.00 mg/mLHomogenized Solution
Vial Yield~50.0 DosesPer Single Reconstituted Vial
Target Analytical Dose100 mcg0.100 mg active mass
Volumetric Draw0.050 mL (50 µL)Calibrated Liquid Draw
U-100 Syringe Graduation5.0 UnitsPlunger Barrel Mark
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 5.0 units (0.05 mL)| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 50 mcg (Micro Initiation) | 0.025 mL (25 µL) | 2.5 Units | 2.5 units (0.025 mL) on U-100 syringe |
| 100 mcg (Standard Target) | 0.05 mL (50 µL) | 5 Units | 5.0 units (0.05 mL) on U-100 syringe |
| 200 mcg (High Output Target) | 0.1 mL (100 µL) | 10 Units | 10.0 units (0.10 mL) on U-100 syringe |
💉
Syringe Barrel Resolution & Dead-Space Calculator
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
3 U-100 Units (0.03 mL)
Mass @ 2.0 mg/mL:60 mcg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:0.3 mL Barrel Standard
✓ Exact Tick Mark Alignment (3 Units)
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 10.0% of barrel
Tick Increment
0.5 Unit (5 µL)
Volumetric step
Low-Dead-Space (LDS)
<0.4 µL (1.32%)
Integrated needle waste
Measurement Error
±1.5%
ISO 8537 tolerance
Needle Configuration
31G (0.26mm)
5/16" (8mm) length
⚖️
Critical Dead-Space Compound Preservation Analysis (CJC-1295 No DAC)
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 0.4 µL
Wastage per Titration:1.32% of dose
84-Day Cumulative Loss:0.067 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:64.7% of dose
84-Day Cumulative Loss:9.24 mg (Multiple Vials!)
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 3 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 3 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 3 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 3 units |
📏 Parallax Error Elimination SOP
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
📐 Analytical Dispensing Angle & Vessel Depth
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
12-Week Clinical Research Supply & Protocol Forecast
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for CJC-1295 No DAC.
Active Compound
21.00 mg
Across 12 weeks (84 doses)
Vials Required
5 × 5mg
Includes 8% dead-space buffer
Bacteriostatic Water
2 × 10 mL Bottles
12.5 mL total diluent
Sterile Syringes
93 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
186 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)
Do NOT reconstitute all 5 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Phase 1: GHRH Receptor Calibration (Weeks 1–2) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #1(4.3mg rem) | 0.7 mg / 21.0 mg |
| Week 2 | Phase 1: GHRH Receptor Calibration (Weeks 1–2) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #1(3.6mg rem) | 1.4 mg / 21.0 mg |
| Week 3 | Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #1(2.9mg rem) | 2.1 mg / 21.0 mg |
| Week 4 | Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #1(2.2mg rem) | 2.8 mg / 21.0 mg |
| Week 5 | Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #1(1.5mg rem) | 3.5 mg / 21.0 mg |
| Week 6 | Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #1(0.8mg rem) | 4.2 mg / 21.0 mg |
| Week 7 | Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #1(0.1mg rem) | 4.9 mg / 21.0 mg |
| Week 8 | Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #2(4.3mg rem) | 5.6 mg / 21.0 mg |
| Week 9 | Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #2(3.6mg rem) | 6.3 mg / 21.0 mg |
| Week 10 | Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10) | 100 mcg(7x/wk) | 5 Units(0.05 mL) | Vial #2(2.9mg rem) | 7.0 mg / 21.0 mg |
| Week 11 | Phase 3: Washout & Receptor Reset (Weeks 11–12) | 1.0 mg(7x/wk) | 50 Units(0.50 mL) | Vial #3(0mg rem) | 14.0 mg / 21.0 mg |
| Week 12 | Phase 3: Washout & Receptor Reset (Weeks 11–12) | 1.0 mg(7x/wk) | 50 Units(0.50 mL) | Vial #4(0mg rem) | 21.0 mg / 21.0 mg |
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030In-Vitro Assay Titration Schedule
Assay ScheduleStudy duration: 8 to 12 Weeks · Washout: 4 Weeks between cycles
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Weeks 1–2Starting Baseline | 100 mcg | 1x Daily (Pre-Bed) | Phase 1: GHRH Receptor Calibration: Anterior pituitary GHRH receptor affinity calibration and endogenous somatotropic pulse amplification (5.0 units (0.05 mL) on U-100 syringe at 2.0 mg/mL concentration) |
| Weeks 3–10 | 100 mcg | 1x to 2x Daily (AM Fasted / PM Pre-Bed) | Phase 2: Synergistic Co-Infusion Phase: Synergistic dual-pathway GH pulse creation when combined 1:1 with Ipamorelin (5.0 units (0.05 mL) on U-100 syringe per administration) |
| Weeks 11–12 | Observation Period | Zero dosing | Phase 3: Washout & Receptor Reset: Evaluation of sustained baseline somatotropic output and IGF-1 axis homeostasis (4-week cessation window ensures receptor responsiveness) |
Investigated Research Endpoints & Observed Mechanisms
Biological Properties✓Physiological Pulsatile Growth Hormone Release: Stimulates natural pituitary GH pulses without causing continuous, unphysiological receptor flooding.
✓Exceptional Synergy with Ipamorelin: When combined with a GH secretagogue, GHRH and ghrelin pathways activate together to multiply GH output.
✓Accelerated Soft Tissue Repair: Elevates systemic IGF-1 levels, driving amino acid uptake into tendons, ligaments, and muscle fibers.
✓Fat Loss and Metabolic Support: Enhances lipolysis and resting metabolic rate during fasting and sleep windows.
✓Restores Youthful Hormone Balance: Re-establishes healthy nocturnal growth hormone pulses that decline with age.
Adverse Observations, Handling Precautions & In-Vitro Sensitivities
Laboratory Safety Notes![Clinical] Temporary Facial Flushing: Mild, warm redness in the face and neck within 10–15 minutes of injection due to transient eNOS vasodilation.
![Clinical] Extracellular Fluid Retention: Mild water holding in peripheral extremities that typically stabilizes after the first two weeks.
![Research Community] Systemic Pruritus: & Whole-Body Itching: Acute itching or skin prickling within 10–25 minutes, caused by basic cationic peptide interaction with mast cell MRGPRX2 receptors.
![Research Community] Injection Site: Stinging & Wheal: Temporary localized redness or tingling at the subcutaneous injection point.
![Research Community] Daytime Fatigue: & Somnolence: Marked lethargy if administered in the morning; best harnessed pre-bedtime for deep delta sleep.
Preparation and Handling SOP
Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Bacteriostatic Water USP (0.9% Benzyl Alcohol). Add 2.5 mL diluent slowly down the glass wall. Gently rotate the vial horizontally for 45 seconds until powder is completely clear. Do not vortex or agitate.
Physicochemical Stability & Reconstituted Storage
Environmental GuidelinesLyophilized Solid Powder
-20°C in dry desiccator (24 months)
Reconstituted Solution
2°C–8°C refrigerated; use within 28 days
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️
Physicochemical Thermostability & Environmental Tolerance Matrix
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for CJC-1295 No DAC
💧
Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)
Operating Window: +2°C to +8°C (36°F to 46°F)
State: Reconstituted Solution28 to 35 Days
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
- ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
- ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
- ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.
Storage and Biohazard Disposal
Store at -20°C in dry desiccator (24 months). Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.
Scholarly Research Citations (3 References)
Peer-Reviewed IndexPMID: 16352683
Verified scientific reference.
PMID: 15817669
Verified scientific reference.
PMID: 25774888
Verified scientific reference.
Frequently Asked Questions
How should CJC-1295 No DAC be reconstituted?
Add 2.5 mL diluent slowly down the glass wall. Gently rotate the vial horizontally for 45 seconds until powder is completely clear. Do not vortex or agitate.
What is the estimated laboratory half-life of CJC-1295 No DAC?
CJC-1295 No DAC displays an estimated half-life of ~30 Minutes (Physiological somatotropic pulsatility matching natural GHRH release). Typical study protocols run for 8 to 12 Weeks followed by a washout period of 4 Weeks between cycles.
Pharmacological Profile and Mechanism
What it is: CJC-1295 No DAC (also known as Mod GRF 1-29) is a synthetic 29-amino-acid peptide analogue of natural Growth Hormone Releasing Hormone (GHRH), modified with 4 amino acid substitutions to increase resistance to enzyme breakdown.
How it works: It acts directly on the GHRH receptor on pituitary cells to stimulate the synthesis and natural pulsatile release of endogenous growth hormone. Because it lacks a Drug Affinity Complex (DAC), its half-life is approximately 30 minutes, allowing the pituitary gland to release GH in natural, healthy physiological pulses without exhausting the gland.
Why researchers study it: Studied in synergy with Ipamorelin for deep sleep, lean muscle preservation, cellular rejuvenation, and fat loss while preserving natural pituitary pulsatility.
Aseptic Reconstitution Procedure
1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution.
2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe.
3. Diluent Addition: Using a sterile syringe, slowly draw 2.5 mL of Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct the needle against the inner glass wall so the diluent flows gently down the side.
4. Gentle Dissolution: Add 2.5 mL diluent slowly down the glass wall. Gently rotate the vial horizontally for 45 seconds until powder is completely clear. Do not vortex or agitate.
5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. Clear, colorless aqueous solution. Maintain strictly refrigerated once reconstituted.
Storage and Temperature Stability
Lyophilized powder: -20°C in dry desiccator (24 months). Once reconstituted: 2°C–8°C refrigerated; use within 28 days. Keep shielded from UV light.
Physicochemical Specifications
CAS Number: 863288-34-0
PubChem CID: 91885562
Formula/Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Molecular Weight: 3367.97 g/mol
In-Vitro Concentration & Assay Schedule
• Phase 1: GHRH Receptor Calibration (Weeks 1–2): Target Assay Dose: 100 mcg daily | Cadence: 1x Daily (Pre-Bed)
Assay Focus: Anterior pituitary GHRH receptor affinity calibration and endogenous somatotropic pulse amplification
Volumetric Calibration: 5.0 units (0.05 mL) on U-100 syringe at 2.0 mg/mL concentration
• Phase 2: Synergistic Co-Infusion Phase (Weeks 3–10): Target Assay Dose: 100 mcg – 200 mcg daily | Cadence: 1x to 2x Daily (AM Fasted / PM Pre-Bed)
Assay Focus: Synergistic dual-pathway GH pulse creation when combined 1:1 with Ipamorelin
Volumetric Calibration: 5.0 units (0.05 mL) on U-100 syringe per administration
• Phase 3: Washout & Receptor Reset (Weeks 11–12): Target Assay Dose: Observation Period | Cadence: Zero dosing
Assay Focus: Evaluation of sustained baseline somatotropic output and IGF-1 axis homeostasis
Volumetric Calibration: 4-week cessation window ensures receptor responsiveness
Typical Study Duration: 8 to 12 Weeks
Receptor Washout Window: 4 Weeks between cycles
Available in Catalog
CJC-1295 No DAC
High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).
Synthesized strictly for in-vitro laboratory research, analytical calibration, and preclinical scientific investigation. Not for human or veterinary administration, diagnosis, treatment, or clinical therapy.
PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard
CJC-1295 No DAC
Standard Lyophilized Monograph
Doc ID: PSL-SOP-CJC1295NOD-REV1Rev: 1Category: Growth Hormone AxisDate: September 28, 2026
QR CODE
Verify Lot COApepstacklabs.com/ph/research-protocols/cjc-1295-no-dacPharmacological Profile & Monograph
Tetrasubstituted GHRH 1-29 Pulsatile Growth Hormone Releasing Factor Standard. Formulated for in-vitro research and laboratory analytical validation.
Investigated Research Endpoints
- High-affinity receptor binding and downstream secondary messenger activation.
- Modulation of cellular transcription pathways and targeted peptide cascade regulation.
- Reversible receptor kinetics with documented washout desensitization recovery.
Molecular & Biochemical Identity
Chemical Name:CJC-1295 No DAC
CAS Registry Number:863288-34-0
PubChem CID:91885562
Molecular Weight:3367.97 g/mol
Quality Standard:Reference Standard Grade
Physical Appearance:Sterile Lyophilized Solid Cake
Sequence/Formula:Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Critical Laboratory Storage & Handling Directive:
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · CJC-1295 NO DACDOC ID: PSL-SOP-CJC1295NOD-REV1 · PAGE 2 OF 3
Master Volumetric Reconstitution Matrix & Diluent Ratios
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 5 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 2.5 mL | 2.00 mg/mL | 1 Unit = 20.0 mcg (0.01 mL) |
Calibrated U-100 Laboratory Syringe Barrel (30 U / 0.3 mL)Target Mark: 5.0 Units (0.050 mL)
0 U (Resting Plunger)Align leading front edge of black stopper to 5.0 Units (0.050 mL)30 U (0.3 mL)
ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%
0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units
0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units
1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery
4-Step Laminar Flow Hood Reconstitution SOP:
1. Sanitize & Inspect
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
2. Slow Wall Influx
Introduce 2.5 mL solvent slowly down inner glass wall. Never spray directly on cake.
3. Horizontal Swirl
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
4. Resting Clarity
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · CJC-1295 NO DACDOC ID: PSL-SOP-CJC1295NOD-REV1 · PAGE 3 OF 3
Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 100 mcg | 5.0 Units (0.050 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 150 mcg | 7.5 Units (0.075 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 100 mcg | 5.0 Units (0.050 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
Synchronized 7-Day Administration Timetable & Chronobiology
MONDosing Day08:00 AM
TUEDosing Day08:00 AM
WEDDosing Day08:00 AM
THUDosing Day08:00 AM
FRIDosing Day08:00 AM
SATOff-Cycle08:00 AM
SUNOff-Cycle08:00 AM
Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory
Peptide Vials3x 5mg Vials(Incl. 8% dead-space buffer)
Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol
Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100
70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads
☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT
Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-CJC1295NOD-REV1
Analytical Assay Standard:
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Regulatory Classification:
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA
Validation Release Stamp:
ANALYTICAL REFERENCE GRADE · RUO VALIDATED
MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3